Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open-label Clinical Study of GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases

NCT07122076 is registered in ClinicalTrials.gov with Grit Biotechnology as lead sponsor.

NCT NCT07122076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07122076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open-label Clinical Study of GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases
Lead sponsor
Grit Biotechnology
Phase
Phase 1
Overall status
Recruiting
Start date
August 22, 2025
Completion date
August 21, 2028
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases